Edgewise Therapeutics (NASDAQ:EWTX) Upgraded by Zacks Investment Research to Hold

Edgewise Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Edgewise Therapeutics Upgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Edgewise Therapeutics (NASDAQ:EWTX) Upgraded by Zacks Investment Research to Hold